Benzimidazole derivative compounds and their uses

Benzimidazole derivative compounds address the limitations of existing PPIs and P-CABs by enhancing solubility and efficacy as gastric acid secretion inhibitors, ensuring rapid and sustained action regardless of pH changes, facilitating diverse formulation options.

JP2024542760AActive Publication Date: 2024-11-15PHARMGEN SCI INC
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2024532846
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-08
Filing Date
2022-12-07
Publication Date
2024-11-15
Estimated Expiration
2042-12-07

AI Technical Summary

Technical Problem

Existing proton pump inhibitors (PPIs) and potassium ion competitive acid blockers (P-CABs) face limitations such as slow onset of action, short half-life, and poor solubility in neutral aqueous solutions, particularly tegoprazan, which affects bioavailability and formulation versatility.

Method used

Development of benzimidazole derivative compounds represented by general formula 1 or 2, which form pharmaceutically acceptable salts or stereoisomers, offering improved neutral water solubility and gastric acid secretion suppression, functioning as potassium ion-competitive acid blockers (P-CABs) with a reversible bond to the proton pump.

Benefits of technology

The benzimidazole derivatives exhibit enhanced gastric acid secretion inhibition, providing quick onset and long-lasting efficacy, unaffected by pH changes, and are easily formulated into various drug preparations, including injections.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542760000001
    Figure 2024542760000001
  • Figure 2024542760000002
    Figure 2024542760000002
  • Figure 2024542760000003
    Figure 2024542760000003
Patent Text Reader

Abstract

The present invention relates to a benzimidazole derivative compound represented by general formula 1 or 2, which exhibits an inhibitory effect on gastric acid secretion, a pharmaceutical composition containing the same as an active ingredient, and uses thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a benzimidazole derivative compound and uses thereof, and more particularly to a benzimidazole derivative compound represented by the following general formula 1 or general formula 2, or a pharma- ceutically acceptable salt or stereoisomer thereof, and uses thereof:

[0002] JPEG2024542760000001.jpg62118

[0003] JPEG2024542760000002.jpg72136 [Background technology]

[0004] Gastric acid plays a positive role in digesting proteins, absorbing minerals such as calcium and iron powder, sterilizing harmful microorganisms in ingested foods, etc. However, because gastric acid is very acidic with a pH of about 1 to 2, if excessive gastric acid is secreted or refluxes into the esophagus, it may cause gastritis, gastric ulcers, and gastroesophageal reflux disease (GERD).

[0005] Gastric acid secretion is initiated by the proton pump (H + / K + This is carried out by the proton pump (ATPase). Various gastric acid secretion stimulating factors cause the proton pump to consume ATP (adenosine triphosphate) and excrete hydrogen ions into the gastric cavity by a one-to-one exchange between hydrogen ions in the cytoplasm and potassium ions in the gastric cavity.

[0006] As gastric acid secretion inhibitors, H2 receptor antagonists (H2 RAs) and proton pump inhibitors (INH inhibitors; PPIs) have been representatively used. However, H2 RAs only block the histamine pathway that stimulates gastric acid secretion, rather than directly suppressing the proton pump, and therefore only show partial effects. In addition, PPIs are prodrugs, and as they are activated by gastric acid before they exert their effects, they must be taken before meals, and because of their slow onset of action and short half-life, they are limited in their ability to suppress the symptoms of nocturnal acid breakthrough (NAB). Therefore, there is a need for the development of gastric acid secretion inhibitors with a novel mechanism that can compensate for these shortcomings.

[0007] Recently, vonoprazan (Japan, 2015) and tegoprazan (Korea, 2019) have been released on the market as potassium-competitive acid blockers (P-CABs), which are new types of gastric acid secretion inhibitors. Compared to existing PPIs, P-CAB drugs have 5 to 100 times improved proton pump inhibition, which secretes gastric acid, and exert stronger efficacy than PPIs. In addition, in terms of mechanism of action, existing PPIs are prodrugs that require an activation process in acid, but P-CABs do not require an activation process. In particular, while PPIs form irreversible covalent bonds with proton pumps, P-CABs bind reversibly, which has the advantage of a very fast onset time, a long duration of action, and the ability to be taken regardless of food.

[0008] However, among the P-CAB drugs, tegoprazan (Korea, 2019) has pH-dependent aqueous solubility, and is a poorly soluble drug, especially in neutral aqueous solutions. Due to this characteristic, when the pH in the gastric cavity rises to neutral, such as after a meal, the solubility of the drug decreases, resulting in a decrease in bioavailability, and it is difficult to formulate into a wide variety of preparations, such as neutral injections. [Prior art documents] [Patent documents]

[0009] [Patent Document 1] Republic of Korea Publication Patent No. 10-2018-0030412 [Patent Document 2] Republic of Korea Publication Patent No. 10-2019-0005674 Summary of the Invention [Problem to be solved by the invention]

[0010] An object of the present invention is to provide a novel benzimidazole derivative compound represented by general formula 1 or 2, which exhibits gastric acid secretion inhibitory activity.

[0011] Another object of the present invention is to provide a pharmaceutical composition for inhibiting gastric acid secretion, which comprises said compound as an active ingredient.

[0012] It is still another object of the present invention to provide a pharmaceutical composition for preventing or treating diseases induced by impaired gastric acid secretion, comprising said compound as an active ingredient. [Means for solving the problem]

[0013] According to one aspect of the present invention, there is provided a benzimidazole derivative compound represented by the following general formula 1 or 2, or a pharma- ceutically acceptable salt or stereoisomer thereof:

[0014] JPEG2024542760000003.jpg62118

[0015] JPEG2024542760000004.jpg66118

[0016] JPEG2024542760000005.jpg53163

[0017] The benzimidazole derivative compound of the present invention represented by general formula 1 or general formula 2 can form a pharmaceutically acceptable salt. The pharmaceutically acceptable salt may include, but is not limited to, an alkali metal or alkaline earth metal salt formed by, for example, sodium, lithium, potassium, calcium, magnesium, etc. The benzimidazole derivative compound of the present invention represented by general formula 1 or general formula 2 can be converted into its salt by a conventional method.

[0018] On the other hand, the compounds of the present invention may have asymmetric carbon centers and therefore may exist as R or S isomers, racemates, partial stereoisomeric mixtures and individual partial stereoisomers, and all of these isomers and mixtures are included within the scope of the present invention.

[0019] In this specification, for ease of explanation, unless otherwise specified, the benzimidazole derivative compound of general formula 1 or general formula 2 is used to mean the compound of general formula 1 or general formula 2, its pharma- ceutically acceptable salts, and stereoisomers.

[0020] Throughout this specification, in defining the benzimidazole derivative compounds of general formula 1 or general formula 2, the concepts defined for substituents as below are used.

[0021] Unless otherwise indicated, the term "alkyl" in this disclosure refers to the radical of a straight or branched chain saturated aliphatic hydrocarbon group having, for example, 1 to 7 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1-ethylpropyl, and 1,2-dimethylpropyl.

[0022] Unless otherwise indicated, the term "cycloalkyl" in this disclosure refers to a radical of a cyclic, saturated aliphatic hydrocarbon group having, for example, 3 to 7 carbon atoms. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.

[0023] According to one embodiment of the present invention, in the above general formula 1 or general formula 2, R2 and R3 can each independently be hydrogen, C1-C7 alkyl or C3-C7 cycloalkyl.

[0024] According to another embodiment of the present invention, in the above general formula 1 or general formula 2, R2 and R3 can each independently be hydrogen or C1-C5 alkyl.

[0025] Representative examples of the benzimidazole derivative compounds of the above general formula 1 or 2 according to the present invention include, but are not limited to, the following compounds:

[0026] Diisopropyl (S)-(4-((5,7-difluorochroman-4-yl)oxy)-6-(dimethylcarbamoyl)-2-methyl-1H-benzo[d]imidazol-1-yl)phosphonate; (S)-Di-tert-butyl(4-((5,7-difluorochroman-4-yl)oxy)-6-(dimethylcarbamoyl)-2-methyl-1H-benzo[d]imidazol-1-yl)methyl)phosphate; tert-Butyl ((4-(S)-5,7-difluorochroman-4-yl)oxy)-6-(dimethylcarbamoyl)-2-methyl-1H-benzo[d]imidazol-1-yl)methyl)hydrogen phosphate; (S)-(4-((5,7-difluorochroman-4-yl)oxy)-6-(dimethylcarbamoyl)-2-methyl-1H-benzo[d]imidazol-1-yl)methyl dihydrogen phosphate; Sodium (S)-tert-butyl(4-((5,7-difluorochroman-4-yl)oxy)-6-(dimethylcarbamoyl)-2-methyl-1H-benzo[d]imidazol-1-yl)methyl)phosphate; and Sodium (S)-(4-((5,7-difluorochroman-4-yl)oxy)-6-(dimethylcarbamoyl)-2-methyl-1H-benzo[d]imidazol-1-yl)methyl phosphate.

[0027] According to another aspect of the present invention, there is provided a pharmaceutical composition for inhibiting gastric acid secretion, comprising a benzimidazole derivative compound of the above general formula 1 or general formula 2, or a pharma- ceutically acceptable salt or stereoisomer thereof, together with a pharma- ceutically acceptable carrier.

[0028] According to another aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating a disease induced by impaired gastric acid secretion, comprising a benzimidazole derivative compound of the above general formula 1 or general formula 2, or a pharma- ceutically acceptable salt or stereoisomer thereof, together with a pharma- ceutically acceptable carrier.

[0029] A "pharmaceutical composition" according to the present invention may contain, in addition to the active compound of the present invention, other chemical components such as a carrier, a diluent, an excipient, etc. Thus, the pharmaceutical composition may include, as needed, a pharma- ceutically acceptable carrier, a diluent, an excipient, or a combination thereof.

[0030] According to another embodiment of the present invention, the disease induced by impaired gastric acid secretion may be, but is not limited to, a gastrointestinal disease, a gastroesophageal disease, gastroesophageal reflux disease (GERD), peptic ulcer, gastric ulcer, duodenal ulcer, NSAIDs-induced ulcer, gastritis, Helicobacter pylori infection, dyspepsia, functional dyspepsia, Zollinger-Ellison syndrome, non-erosive gastroesophageal reflux disease (NERD), visceral referred pain (visceral pain, visceral pain), heartburn, nausea, esophagitis, dysphagia, sialorrhea, airway disorder or asthma. Effect of the Invention

[0031] The benzimidazole derivative compound represented by general formula 1 or 2 according to the present invention exhibits an inhibitory effect on gastric acid secretion, and can function as a potassium-competitive acid blocker (P-CAB), and can be used as a gastric acid secretion inhibitor, or as a preventive or therapeutic agent for diseases induced by impaired gastric acid secretion. In addition, the benzimidazole derivative compound represented by general formula 1 or 2 according to the present invention has a significantly improved neutral water solubility compared to tegoprazan, which has been developed as a gastric acid secretion inhibitor, and is not affected by the pH of the body, such as food, and is easy to formulate into preparations such as injections. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0032] The present invention will be described in more detail below with reference to Production Examples and Examples, however, these Examples are merely illustrative of the present invention and the scope of the present invention is not limited thereto.

[0033] The explanation of abbreviations used in the examples below is as follows:

[0034] ACN: Acetonitrile DMF: N,N-dimethylformamide EtOAc: Ethyl acetate FA: Formic acid MeOH: Methanol

[0035] Example 1: Preparation of diisopropyl(S)-(4-((5,7-difluorochroman-4-yl)oxy)-6-(dimethylcarbamoyl)-2-methyl-1H-benzo[d]imidazol-1-yl)phosphonate

[0036] JPEG2024542760000006.jpg8355

[0037] 7-[[(4S)-5,7-difluoro-3,4-dihydro-2H-chromen-4-yl]oxy]-N,N,2-trimethyl-3H-benzimidazole-5-carboxamide (80 mg, 0.21 mmol) was dissolved in dry dimethylformamide (DMF) (2 mL), and then 60% NaH (12.39 mg, 0.31 mmol) was added under a nitrogen atmosphere at 0° C. and stirred at room temperature for 30 minutes. Diisopropyl phosphorochloridate (53.85 mg, 0.27 mmol) was added to the reaction mixture at 0° C. and stirred at room temperature for 1 hour. After the reaction was completed, the mixture was extracted with EtOAc, washed with brine, dried with anhydrous Na2SO4, and then separated by column chromatography (EtOAc:Hexane:MeOH=6:6:1) to obtain the target compound diisopropyl (S)-(4-((5,7-difluorochroman-4-yl)oxy)-6-(dimethylcarbamoyl)-2-methyl-1H-benzo[d]imidazol-1-yl)phosphonate (43 mg, 37%) as a white solid.

[0038] NMR(DMSO-d6): 7.13 (1H), 6.93(s, 1H), 6.83(t, 1H), 6.70(d, 1H), 6.03(s, 1H), 4.43~4.37(m, 3H), 4.25(t, 1H), 2.97(s, 6H), 2.45(s, 3H), 2.24(d, 1H), 2.07(t, 1H), 1.24(d, 12H); MS+:552.44

[0039] Example 2: Preparation of (S)-di-tert-butyl((4-((5,7-difluorochroman-4-yl)oxy)-6-(dimethylcarbamoyl)-2-methyl-1H-benzo[d]imidazol-1-yl)methyl)phosphate

[0040] JPEG2024542760000007.jpg9454

[0041] 7-[[(4S)-5,7-difluoro-3,4-dihydro-2H-chromen-4-yl]oxy]-N,N,2-trimethyl-3H-benzimidazole-5-carboxamide (1,000mg, 2.58mmol) was dissolved in dry DMF (25.8mL), and then 60% NaH (154.89mg, 3.87mmol) was added under nitrogen atmosphere at 0℃ and stirred at room temperature for 30 minutes. Diisopropyl phosphorochloridylate (1,336mg, 5.16mmol) was added to the reaction mixture at 0℃ and stirred at room temperature for 1 hour. After the reaction was completed, the mixture was extracted with EtOAc, washed with brine, dried with anhydrous Na2SO4, and then separated by column chromatography (EtOAc:Hexane:MeOH=6:6:1) to obtain the target compound (S)-di-tert-butyl(4-((5,7-difluorochroman-4-yl)oxy)-6-(dimethylcarbamoyl)-2-methyl-1H-benzo[d]imidazol-1-yl)methyl)phosphate (812 mg, 52%) as a white solid.

[0042] NMR(DMSO-d6): 7.30(s, 1H), 6.94(s, 1H), 6.81(t, 1H), 6.76(d, 1H), 6.14(s, 1H), 6.02(d, 2H), 4.36(d, 1H), 4.22(d, 1H), 2.97(s, 6H), 2.61(s, 3H), 2.22(d, 1H), 2.07(t, 1H), 1.38~1.26(m, 18H); MS+: 610.33

[0043] Example 3: Preparation of tert-butyl((4-(((S)-5,7-difluorochroman-4-yl)oxy)-6-(dimethylcarbamoyl)-2-methyl-1H-benzo[d]imidazol-1-yl)methyl)hydrogen phosphate

[0044] JPEG2024542760000008.jpg8354

[0045] (S)-di-tert-butyl (4-((5,7-difluorochroman-4-yl)oxy)-6-(dimethylcarbamoyl)-2-methyl-1H-benzo[d]imidazol-1-yl)methyl) phosphate (295 mg, 0.49 mmol) was dissolved in DMF (4.86 mL), and then 4N HCl (1.4 mL) was added at 0 ° C. and stirred at room temperature for 90 minutes. After the reaction was completed, the product was separated by reverse phase column chromatography (0.1% FA) and freeze-dried to obtain the target compound tert-butyl ((4-(S)-5,7-difluorochroman-4-yl)oxy)-6-(dimethylcarbamoyl)-2-methyl-1H-benzo[d]imidazol-1-yl)methyl) hydrogen phosphate (74.2 mg, 27%) as a white solid.

[0046] NMR(DMSO-d6): 7.31(s, 1H), 6.94(s, 1H), 6.81(t, 1H), 6.71(d, 1H), 6.15(s, 1H), 5.96(d, 2H), 4.37(d, 1H), 4.23(t, 1H), 2.98(s, 6H), 2.64(s, 3H), 2.24(d, 1H), 2.07(m, 1H), 1.26(s, 9H); MS+:554.47

[0047] Example 4: Preparation of (S)-(4-((5,7-difluorochroman-4-yl)oxy)-6-(dimethylcarbamoyl)-2-methyl-1H-benzo[d]imidazol-1-yl)methyldihydrogen phosphate

[0048] JPEG2024542760000009.jpg6951

[0049] tert-Butyl ((4-(S)-5,7-difluorochroman-4-yl)oxy)-6-(dimethylcarbamoyl)-2-methyl-1H-benzo[d]imidazol-1-yl)methyl) hydrogen phosphate (200mg, 0.33mmol) was dissolved in DMF (6.57mL), and then 4N HCl (0.5mL) was added at 0°C and stirred at room temperature for 90 minutes. After the reaction was completed, the product was separated by reverse phase column chromatography (0.1% FA) and freeze-dried to obtain the target compound (S)-(4-((5,7-difluorochroman-4-yl)oxy)-6-(dimethylcarbamoyl)-2-methyl-1H-benzo[d]imidazol-1-yl)methyl dihydrogen phosphate (64.1mg, 35%) as a white solid.

[0050] NMR(DMSO-d6): 7.31(s, 1H), 6.94(s, 1H), 6.81(t, 1H), 6.71(d, 1H), 6.14(s, 1H), 5.95(d, 2H), 4.37(d, 1H), 4.22(t, 1H), 2.98(s, 6H), 2.64(d, 3H), 2.25(d, 1H), 2.07(m, 1H); MS+:498.29

[0051] Example 5: Preparation of sodium (S)-tert-butyl((4-((5,7-difluorochroman-4-yl)oxy)-6-(dimethylcarbamoyl)-2-methyl-1H-benzo[d]imidazol-1-yl)methyl)phosphate

[0052] JPEG2024542760000010.jpg6946

[0053] tert-Butyl ((4-(S)-5,7-difluorochroman-4-yl)oxy)-6-(dimethylcarbamoyl)-2-methyl-1H-benzo[d]imidazol-1-yl)methyl)hydrogen phosphate (52.8mg, 0.095mmol) was dissolved in ACN:H2O=1:1 (9.5mL), and then NaOH (4.2mg, 0.105mmol) was added and stirred at room temperature for 1 minute. After the reaction was completed, the mixture was freeze-dried to obtain the target compound sodium (S)-tert-butyl (4-((5,7-difluorochroman-4-yl)oxy)-6-(dimethylcarbamoyl)-2-methyl-1H-benzo[d]imidazol-1-yl)methyl)phosphate (54mg, 98%) as a white solid.

[0054] NMR(D2O): 7.47(s, 1H), 7.13(s, 1H), 6.65~6.56(m, 2H), 5.96~5.93(m, 3H), 4.51~4.45(m, 2H), 3.15(s, 3H), 3.05(s, 3H), 2.72(s, 3H), 2.39(d, 1H), 2.22~2.14(m, 1H), 1.04(s, 9H); MS+: 554.35

[0055] Example 6: Preparation of sodium (S)-(4-((5,7-difluorochroman-4-yl)oxy)-6-(dimethylcarbamoyl)-2-methyl-1H-benzo[d]imidazol-1-yl)methyl phosphate

[0056] JPEG2024542760000011.jpg7148

[0057] (S)-(4-((5,7-difluorochroman-4-yl)oxy)-6-(dimethylcarbamoyl)-2-methyl-1H-benzo[d]imidazol-1-yl)methyl dihydrogen phosphate (51.6mg, 0.104mmol) was dissolved in ACN:H2O=1:1 (10.4mL), and then NaOH (8.7mg, 0.218mmol) was added and stirred at room temperature for 1 minute. After the reaction was completed, the mixture was freeze-dried to obtain the target compound sodium (S)-(4-((5,7-difluorochroman-4-yl)oxy)-6-(dimethylcarbamoyl)-2-methyl-1H-benzo[d]imidazol-1-yl)methyl phosphate (52mg, 93%) as a white solid.

[0058] NMR(D2O): 7.52(s, 1H), 7.11(s, 1H), 6.65~6.58(m, 2H), 5.95(s, 1H), 5.84(d, 2H), 4.48~4.45(m, 2H), 3.15(s, 3H), 3.06(s, 3H), 2.71(s, 3H), 2.41(d, 1H), 2.22~2.13(m, 1H); MS+: 498.33

[0059] Experimental Example 1: Water solubility test (pH 6.8)

[0060] Each test substance was weighed into a glass vial to give a concentration of 5.12 mg / ml, and then 0.5 M Tris-HCl (pH 6.8, T&I Corporation, BTH-9168) was added, mixed for 1 minute using a vortex, and treated with an ultrasonic disintegrator for 30 minutes to prepare a solution. The solution was observed visually and then photographed. If the substance was not completely dissolved, further buffer solution was added to prepare a solution, and the observation was repeated. The concentration at the time of complete dissolution was confirmed to evaluate the solubility. Tegoprazan was used as a comparative compound. The measurement results are shown in Table 1 below.

[0061] JPEG2024542760000012.jpg43119

[0062] As is clear from Table 1 above, the compounds of Examples 3 and 4 according to the present invention exhibited 128-fold improved aqueous solubility (pH 6.8) compared to the comparative compound, and the compounds of Examples 2, 5, and 6 exhibited 256-fold improved aqueous solubility (pH 6.8) compared to the comparative compound. Thus, the novel benzimidazole derivative compounds of the present invention, which have significantly improved aqueous solubility, are not affected by the increase in pH in the gastric cavity accompanying feeding, and are easy to formulate into preparations such as injections.

[0063] Experimental Example 2: Confirmation test of gastric acid secretion suppression ability by oral administration

[0064] Test animals (rats) were purchased and acclimatized one week before the test date. After acclimatization, food was removed the day before the test, and fasting was performed for 24 hours using a fasting board. The weight of each individual was measured, and weight rankings were assigned to each group in order, and the weights were randomly distributed so that the average value of each group was uniformly distributed. The test substances (compounds of the examples and comparative compounds) were dissolved in 0.5% methylcellulose solution, and tegoprazan was used as the comparative compound. The prepared test drug was orally administered to the test animals at a dose of 3 mg / 5 mL / kg, and 30 minutes later, inhalation anesthesia (3% isoflurane) was administered for 3 minutes using an inhalation anesthesia machine. The upper abdomen of the anesthetized test animals was incised to the minimum extent about 1 cm below the left side of the sternum, and the stomach was exposed, and the pyloric ring, which is the connection site between the stomach and duodenum, was tied. The stomach and duodenum were returned to their original positions, and the abdominal incision was carefully sutured together using a surgical stapler. Histamine (7.5mg / 2.5mL / head) was gradually administered subcutaneously at the back of the neck to stimulate gastric acid secretion. Three hours after surgery, the experimental animals were anesthetized with isoflurane, and the stomach was removed by laparotomy. Gastric juice obtained from the removed stomach was transferred to a 15mL conical tube, centrifuged at 5,000 rpm for 10 minutes, and only the supernatant was separated. 0.2mL of the separated gastric juice was diluted with 24.8mL of distilled water to make a total of 25mL of diluted solution, which was then titrated to pH 7 by administering small amounts of 0.01N NaOH. The efficacy was evaluated by calculating the total acidity by adding the amount of gastric juice and the amount of 0.01N NaOH required for titration.

[0065] JPEG2024542760000013.jpg21141

[0066] The measured results are shown in Table 2 below.

[0067] JPEG2024542760000014.jpg48164

[0068] As is clear from Table 2 above, it was confirmed that the compounds of Examples 1, 4 and 6 according to the present invention have a strong ability to inhibit gastric acid secretion in an animal model of gastric acid secretion.

[0069] Experimental Example 3: Confirmation test of gastric acid secretion suppression ability by administration to the duodenum

[0070] Test animals (rats) were purchased and acclimatized one week before the test date. After acclimatization, food was removed the day before the test, and fasting was performed for 24 hours using a fasting board. The weight of each individual was measured, and weight rankings were assigned to each group in order, and the weights were randomly distributed so that the average value of each group was uniformly distributed. The test substances (compounds of the examples and comparative compounds) were dissolved in 0.5% methylcellulose solution, and tegoprazan was used as the comparative compound. The experimental animals were anesthetized by inhalation (3% isoflurane) for 3 minutes using an inhalation anesthesia machine. The upper abdomen of the anesthetized test animals was incised to the minimum extent about 1 cm below the left side of the sternum, and the stomach was exposed, and the pylorus ring, which is the connecting site between the stomach and the duodenum, was tied. The prepared drug was administered into the duodenum at a dose of 1 mg / 5 mL / kg, the stomach and duodenum were returned to their original positions, and the abdominal incision was carefully sutured with a surgical stapler. Histamine (7.5mg / 2.5mL / head) was gradually administered subcutaneously at the back of the neck to stimulate gastric acid secretion. Three hours after surgery, the experimental animals were anesthetized with isoflurane, and the stomach was removed by laparotomy. Gastric juice obtained from the removed stomach was transferred to a 15mL conical tube, centrifuged at 5,000 rpm for 10 minutes, and only the supernatant was separated. 0.2mL of the separated gastric juice was diluted with 24.8mL of distilled water to make a total of 25mL of diluted solution, which was then titrated to pH 7 by administering small amounts of 0.01N NaOH. The efficacy was evaluated by calculating the total acidity by adding the amount of gastric juice and the amount of 0.01N NaOH required for titration.

[0071] JPEG2024542760000015.jpg20139

[0072] The measured results are shown in Table 3 below.

[0073] JPEG2024542760000016.jpg24164

[0074] As is clear from Table 3 above, the compound of Example 6 according to the present invention exhibited improved gastric acid secretion inhibitory activity compared to the comparative compound when administered to the duodenum, which has a neutral pH. Therefore, the compound of Example 6 according to the present invention is expected to exert the same efficacy regardless of pH even after a meal, when the pH in the gastric cavity is neutral, or under various biological environments.

Claims

1. A benzimidazole derivative compound represented by the following general formula 1 or 2, or a pharma- ceutically acceptable salt or stereoisomer thereof:

2. R 2 and R 3 are each independently hydrogen, C 1 -C 7 Alkyl or C 3 -C 7 2. The benzimidazole derivative compound according to claim 1, or a pharma- ceutically acceptable salt or stereoisomer thereof, characterized in that:

3. R 2 and R 3 are each independently hydrogen or C 1 -C 5 The benzimidazole derivative compound according to claim 2, or a pharma- ceutically acceptable salt or stereoisomer thereof, characterized in that it is alkyl.

4. 2. The benzimidazole derivative compound, or a pharma- ceutically acceptable salt or stereoisomer thereof, according to claim 1, characterized in that the pharma-ceutically acceptable salt is an alkali metal or alkaline earth metal salt selected from the group consisting of sodium, lithium, potassium, calcium and magnesium.

5. 5. The benzimidazole derivative compound, or a pharma- ceutically acceptable salt or stereoisomer thereof, according to claim 4, wherein the pharma- ceutically acceptable salt is a sodium salt.

6. The benzimidazole derivative compound according to claim 1, characterized in that the compound of the above general formula 1 or general formula 2 is selected from the following group, or a pharma- ceutically acceptable salt or stereoisomer thereof: Diisopropyl (S)-(4-((5,7-difluorochroman-4-yl)oxy)-6-(dimethylcarbamoyl)-2-methyl-1H-benzo[d]imidazol-1-yl)phosphonate; (S)-Di-tert-butyl(4-((5,7-difluorochroman-4-yl)oxy)-6-(dimethylcarbamoyl)-2-methyl-1H-benzo[d]imidazol-1-yl)methyl)phosphate; tert-butyl((4-(S)-5,7-difluorochroman-4-yl)oxy)-6-(dimethylcarbamoyl)-2-methyl-1H-benzo[d]imidazol-1-yl)methyl)hydrogen phosphate; (S)-(4-((5,7-difluorochroman-4-yl)oxy)-6-(dimethylcarbamoyl)-2-methyl-1H-benzo[d]imidazol-1-yl)methyl dihydrogen phosphate; Sodium (S)-tert-butyl(4-((5,7-difluorochroman-4-yl)oxy)-6-(dimethylcarbamoyl)-2-methyl-1H-benzo[d]imidazol-1-yl)methyl)phosphate; and Sodium (S)-(4-((5,7-difluorochroman-4-yl)oxy)-6-(dimethylcarbamoyl)-2-methyl-1H-benzo[d]imidazol-1-yl)methyl phosphate.

7. A pharmaceutical composition for inhibiting gastric acid secretion, comprising as an active ingredient a benzimidazole derivative compound of general formula 1 or general formula 2 defined in any one of claims 1 to 6, or a pharma- ceutically acceptable salt or stereoisomer thereof, together with a pharma- ceutically acceptable carrier.

8. A pharmaceutical composition for preventing or treating a disease induced by impaired gastric acid secretion, comprising as an active ingredient a benzimidazole derivative compound of general formula 1 or general formula 2 defined in any one of claims 1 to 6, or a pharma- ceutically acceptable salt or stereoisomer thereof, together with a pharma- ceutically acceptable carrier.

9. 9. The pharmaceutical composition for preventing or treating a disease induced by impaired gastric acid secretion according to claim 8, wherein the disease induced by impaired gastric acid secretion is selected from the group consisting of digestive tract disease, gastroesophageal disease, gastroesophageal reflux disease (GERD), peptic ulcer, gastric ulcer, duodenal ulcer, NSAIDs-induced ulcer, gastritis, Helicobacter pylori infection, dyspepsia, functional dyspepsia, Zollinger-Ellison syndrome, non-erosive gastroesophageal reflux disease (NERD), visceral referred pain, heartburn, nausea, esophagitis, dysphagia, sialorrhea, airway disorder and asthma.

Citation Information

Patent Citations

  • Chroman-substituted benzimidazole derivatives and their use as acid pump inhibitors

    JP2009520017A

  • Use of benzimidazole derivatives for nocturnal gastric acid hypersecretion

    JP2018516951A

  • Injectable composition

    JP2020525516A

  • Tablet

    KR1020180030412A

  • Composition for injection

    KR1020190005674A